Travere misses on top, bottom lines, restarts Phase 3
Travere Therapeutics Q1 2026 non-GAAP EPS -$0.40, revenue $127.2M, both miss estimates
- Non-GAAP EPS was -$0.40, representing a 15% year-over-year improvement.
- Adjusted loss measured $0.39 per share, wider than forecasts for a $0.30 loss.
- Revenue totaled $127.2M, up 68% year over year but below the $129.6M forecast.
- U.S. net product sales rose to $124.5 million, driven by FILSPARI, whose sales increased 88% post-FSGS approval.
- Company restarted the Phase 3 HARMONY study of pegtibatinase again.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.